何天有教授“靶向针刺法”治疗中风后吞咽障碍的临床研究

目的:研究何天有教授"靶向针刺法"治疗中风后吞咽障碍的临床疗效。方法:将70例患者按照住院顺序随机分为2组,每组35例。观察组采用何天有教授"靶向针刺法"配合康复训练治疗,对照组给予吞咽障碍治疗仪配合康复训练治疗。分别于治疗前、治疗20次后利用电视透视吞咽功能检查(VFSS)进行吞咽功能评估及比较临床疗效。结果:VFSS评分2组治疗后与同组治疗前比较,差异均有统计学意义(P0.05),治疗后2组比较,差异有统计学意义(P0.05)。有效率观察组为91.43%,对照组为80.00%,2组比较差异有统计学意义(P0.05)。结论:何天有教授"靶向针刺法"配合康复训练是治疗中风后吞咽障碍的一种有效方法。     

化脓性颞下颌关节炎病原菌的分离培养和鉴定

目的 分离、培养和保存化脓性颞下颌关节炎的病原菌，了解其种类，探索合适的培养条件。方法 对近5a就诊的30例化脓性颞下颌关节炎患者，抽取关节液，进行涂片、革兰染色，分别采用血琼脂培养基、室温保存菌种培养基、乳酪消化大豆胨琼脂(TSA)和乳酪消化大豆胨肉汤(TSB)等4种培养基在需氧和厌氧条件下进行细菌培养，并对培养出的细菌进行生化鉴定。结果 关节液涂片细菌检出率为50％(15／30)，细菌培养阳性率为17％(5／30)，培养出的病原菌主要为腐生葡萄球菌和金黄色葡萄球菌，所用的培养基以TSB为佳。结论 作者成功地分离出2种病原菌，其中腐生葡萄球菌为首次发现，但检出率较低，尚需进一步完善培养技术。     

带有双侧部分输尿管的猪膀胱模型在宫腔镜培训中的应用

目的　为获得最大程度模拟人类子宫的宫腔镜精细电切培训用模型。 方法　获取带有双侧部分输尿管的猪膀胱,指导学员进行宫腔镜手术技巧的培训（实验组模型）,同期使用传统的培训模型四腔猪心（对照组模型）,考核为双向性,指导教师以考核内容进行打分,学员则填写调查问卷来评价模型。 结果　3站宫腔镜手术模拟培训中,两组模型训练学员的成绩及学员对模型的评价均有统计学差异（P<0.05）,认为膀胱模型膨起度良好,视野清晰,便于辨识解剖结构,能够更逼真模拟宫腔实际操作的困难状况。 结论　猪膀胱因其最大程度模拟人类子宫及其术中实际困难情境,是宫腔镜技术培训的理想模型。     

改良头皮冠状切口在颧骨复合体骨折中的应用

目的:探讨改良头皮冠状切口在各类颧骨复合体骨折坚固内固定术中的应用。方法:将87例颧骨复合体骨折病例分为改良组和传统组,分别应用改良冠状切口(42例)与传统切口(45例)进行复位和固定,对比分析改良冠状切口的优越性、可能并发症及预防措施。结果:改良组切口均Ⅰ期愈合,随访3⁶个月,面部瘢痕不明显,开口度恢复理想,咬合关系正常,术后秃发率及颞部凹陷率较低,无1例出现面神经功能障碍。传统组中,2例术后第5天出现创区感染,切口延期愈合,术后肿胀反应明显;4例患者术后3月时仍存在面神经功能障碍,术后秃发率及颞部凹陷率较高。结论:改良冠状切口较传统切口具有切口隐蔽、术野暴露好、复位精确、美观效果好、面神经损伤率低等优点,值得推广应用。     

电磁脉冲辐射对原癌基因c-fos调控区的影响

目的　通过研究电磁脉冲 (electromagneticpulse ,EMP)辐射对原癌基因c fos调控区域的影响 ,探讨其诱导细胞功能改变的机制。方法　构建c fos启动区氯霉素乙酰化转移酶 (chloramphenicolacetyl transferase,CAT) ,然后转染HeLa癌细胞株 ,高场强EMP模拟源 (有界波模拟源 )辐射细胞 ,EMP场强为6× 10 4V/m ,脉冲上升时间为 2 0ns ,脉宽为 3 0 μs ,频率为 2 .5个脉冲 /min ,辐射 2min ,处理后 2 0min时观察细胞中CAT的活性。结果　EMP辐射转染的细胞后 2 0min ,转染了P50 0 ( -711～ -2 2 3bp)和P2 50 ( -3 62～-10 0 )的Hela细胞其CAT活性明显高于对照水平的活性 (P <0 .0 1)。结论　EMP辐射可引起c fos基因调控区的 -3 62～ -2 2 5明显改变。     

Percutaneous umbilical blood sampling and umbilical vein transfusions. Rapid serologic differentiation of fetal blood from maternal blood

Percutaneous umbilical blood samples (PUBS), obtained under ultrasound guidance, are used for prenatal diagnosis and management of hemolytic disease of the newborn (HDN) and other fetal disorders. Rapid testing at the time of sampling is vital to distinguish fetal from maternal blood. Blood typing was performed by slide technique in the treatment room during 38 procedures on 25 patients. Anti-I was used to test 50 presumed PUBS; venous I-positive maternal blood was tested in parallel. Because anti-I cannot detect fetal blood after umbilical vein transfusion (UVT) of I-positive donor blood, ABO and Rh blood typing reagents were used to test 29 samples when maternal and fetal or donor blood groups differed. Monoclonal reagents were used for optimal detection of weak AB antigens in fetal blood. Avid, chemically modified anti-D was used for Rh typing. Blood typing showed 27 (34%) of 79 samples to be maternal blood. Fetal blood was obtained in 8 of 10 cases investigated for fetal disorder and in 16 cases of potential HDN (anti-D, 5; -CD, 5; -cE, 2; -K, 2; -c; -E). The absence of HDN (antigen-negative fetus) was determined in 4 cases. UVT afforded live birth of 9 of 10 infants with HDN and was not indicated in two cases.     

Electronic verification of donor-recipient compatibility: the computer crossmatch

Background: This article describes standard operating procedures (SOPs) for a computer crossmatch to replace the immediate-spin crossmatch for ABO incompatibility between patient blood samples submitted for pretransfusion testing and the blood component selected for transfusion. These SOPs were developed following recent changes to the Standards for Blood Banks and Transfusion Services of the American Association of Blood Banks (AABB). Study Design and Methods: SOPs were developed, utilizing currently available software, for pretransfusion testing. The SOP for donor unit processing entails bar code entry of the unit number, component name, and ABO/Rh type; computer entry and interpretation of serologic reactions; warning of discrepancies between bar code-entered blood type and result interpretation; and quarantine of the donor unit in such instances. The SOP for patient sample testing requires bar code entry of specimen accession number, which accesses patient demographics; computer entry and interpretation of ABO/Rh tests; repeat blood typing at the time of crossmatch if only one patient blood type is on record; and warning if there are nonconcordant current and historical blood types. The computer crossmatch SOP requires bar code entry of specimen accession and donor unit numbers; release of group O red cells pending resolution of discrepancies; and immediate-spin crossmatch during computer downtime. Tables validated on- site prompt warning messages and prevent both computer crossmatch and release if blood components of the wrong ABO type are selected. Results: These SOPs meet the requirements of the 15th edition of the AABB Standards. Projected annual time savings at this institution are > 100,000 workload recording units. Further benefits include reduced patient sample volume requirements, less handling of biohazardous material, and elimination of unwanted positive or negative reactions associated with the immediate-spin crossmatch. Release of incompatible blood components when the wrong patient blood type is on record is addressed by requiring the use of group O red cells in the absence of two concordant blood types, one of which must be from a current sample. Conclusion: A combination of existing computer programs and carefully developed SOPs can provide a safe and efficient means of detecting donor-recipient incompatibility without performance of serologic crossmatch.     

Discrepancies in reverse ABO typing due to prozone

Three group O sera manifesting prozone in reverse ABO tests are reported. All were implicated in erroneous blood typing results. One sample failed to react with A1 red cells (RBCs) in immediate-spin (IS) tests, had anti-A and -B titers of 8192 and 2048, respectively, by indirect antiglobulin technique (IAT), and was from a diabetic patient; the parenteral administration of A substance present in porcine insulin is a possible cause of hyperimmunity in this case. The second sample was from the recipient of a single unit of group B fresh-frozen plasma; the serum anti-A and -B titers were 10,240 by IAT, but only weak reactions with A1 and B RBCs were noted in routine IS reverse typing tests; the hyperimmunity in the patient concerned was likely due to crossreacting anti-A, B stimulated by B-active glycoproteins and/or glycolipids in the transfused plasma. The third serum also had anti-A and anti-B IAT titers of 10,240 but did not react with A1 and B RBCs by IS; the hyperimmunity in this case may be related to sepsis from intestinal flora carrying A- and/or B-like antigens. These antibodies lysed A1 and/or B RBCs in tests incubated at room temperature (RT) and strongly agglutinated those RBCs by IS when diluted 10-fold with saline. The absence of the prozone phenomenon in tests with RBCs suspended in diluents containing EDTA is consistent with the previously published mechanism for anti-A prozone: namely, the steric hindrance of agglutination by the C1 component of human complement.(ABSTRACT TRUNCATED AT 250 WORDS)     

Nationwide survey of home transfusion practices

BACKGROUND: Limited information exists on home transfusion practices. STUDY DESIGN AND METHODS: In 1995, a survey requesting data for 1994 was sent to 1273 American Association of Blood Banks (AABB) institutional members and 113 non-AABB home health care agencies that provide out-of-hospital transfusions. RESULTS: Of 943 respondents, 102 provide blood to a home transfusion program, 37 provide blood and run a home transfusion program, and 13 run a home transfusion program only, for a total of 152 (16%) with some involvement in home blood transfusions. Most of the 50 respondents with a home transfusion program are licensed by their state and accredited by the Joint Commission on Accreditation of Healthcare Organizations. All respondents have written policies for home transfusion, and 90 percent require a signed informed-consent document before initiating transfusions in the home. Most have policies requiring that there be a second adult and a telephone in the home, that the home be deemed safe for transfusion, that the patient's physician be readily available, and that the patient have had prior transfusions. The most common component issued by the blood providers was red cells, followed by platelets. White cell-reduced components were always provided by 36 percent of respondents. The most common patient diagnosis was cancer. Home transfusions were provided primarily by registered nurses. Only 14 percent of respondents indicated that the medical director of the blood bank is responsible for approving a patient for home transfusion. A posttransfusion visit is performed by 46 percent of respondents. CONCLUSION: Although most facilities have policies for the administration of home transfusions, there remains marked heterogeneity among blood providers and transfusionists regarding home transfusion practices.     

Can the reading for serologic reactivity following 37 degrees C incubation be omitted?

The need to detect antibodies that agglutinate and/or hemolyze red cells (RBCs) directly at 37 degrees C, but do not react in subsequently performed indirect antiglobulin tests (IATs), is of concern relative to the streamlining and automation of antibody detection methods. To determine incidence and significance of such reactions, data from 87,480 tests, which used low-ionic-strength saline, 10-minute incubation at 37 degrees C, and anti-IgG, were analyzed for unexpected antibodies. There were 3590 positive tests, of which 475 showed reactions at 37 degrees C but not in subsequently performed IATs (37 + IAT-). Of these, 196 reactions were due to autoantibodies or other factors usually considered insignificant with respect to the survival of transfused incompatible RBCs, 176 were due to alloantibodies of questionable clinical significance (M, Lea, P1, etc.), and 103 were associated with alloantibodies of potential clinical significance (63 E, 27 K, 5 Jka, 4 D, 3 cE, and 1 C). This latter reaction was seen in 72 patients, with two 37 + IAT-antibodies occurring in each of 3 patients. Of the 75 potentially significant 37 + IAT-antibodies, 57 were seen in patients recently exposed to homologous RBCs, 13 in patients with a history of transfusion and/or pregnancy, and 5 in patients with no known exposure to homologous RBCs. IAT reactivity was observed in subsequent samples with 27 of these antibodies. The predictive value of a 37 + IAT-test was 21.7 percent for a potentially significant antibody. The incidence was 0.12 percent of all tests for unexpected antibodies.(ABSTRACT TRUNCATED AT 250 WORDS)